Portfolio manager comments — Q1 2025
Fund performance was negative in Q1 2025. The year began strongly with a sharp upturn in the stock market during January that held up into the end of February. The upturn was driven by strong reports in Q4 2024, expectations of peace in Ukraine, and signals for upcoming stimulus measures in Europe. We also saw an increased flow of capital out of the US and into European markets, which strengthened share price performance further.
However, the market declined in March and wiped out the upturn for the entire year. This was primarily due to Trump’s repeated actions about tariffs across the world, which created concerns about stagflation in the US.
Invisio, Truecaller, Afry and the new holding in Asker were the primary contributors in the fund. The first three companies released quarterly figures and news that were well-received by the market. Asker’s IPO was significantly oversubscribed and rose 20% on the first trading day.
Biotage, Sdiptech, Corem and Hexatronic continued to contribute negatively. These companies have temporarily fallen into the background from a historical perspective and relative to similar companies, despite low valuations.
Asker Healthcare, Asmodee and SSAB were the largest investments made by the fund, while the most substantial sales were made in Skanska, Sobi and Truecaller.
We remain positive to an improved industrial economy towards the end of the year and expect a recovery in consumption in Northern Europe. The decline in March has created several attractive investment opportunities, particularly among small and mid-sized companies. At the same time, there is significant uncertainty in the short term about the president’s next move.